Delaware, November 5, 2025 (finance yahoo) -- Braveheart Bio has emerged from stealth with $185 million in Series A funding to advance BHB-1893, a potential best-in-class treatment for hypertrophic cardiomyopathy licensed from China’s Hengrui Pharma. The company plans to launch global late-stage trials in 2026. Led by former HI-Bio CEO Travis Murdoch and chaired by Biogen’s Chris Viehbacher, Braveheart joins a growing wave of biotech startups licensing late-stage drugs from

Salt Lake City, UT, November 5, 2025 (Globe Newswire) -- Recursion (NASDAQ: RXRX), a leading TechBio company integrating AI, biology, and chemistry, announced a planned leadership transition effective January 1, 2026. Co-founder and current CEO Chris Gibson will assume the role of Chairman of the Board, while Najat Khan, Ph.D., currently Chief R&D and Commercial Officer, will become CEO and President. The move aims to ensure continuity as Recursion advances its platform and

Waltham, MA, October 29, 2025 (Business Wire) -- Thermo Fisher Scientific announced a definitive agreement to acquire Clario Holdings, a global leader in digital clinical endpoint data solutions, for $8.875 billion in cash plus potential earnouts. The acquisition enhances Thermo Fisher’s capabilities in AI-driven clinical data integration, enabling pharma and biotech clients to accelerate innovation through deeper, faster insights. Expected to close mid-2026, the deal will

Marlborough, MA, October 17, 2025 (PRNewswire) -- Boston Scientific has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medtech company specializing in minimally invasive neurostimulation therapies for chronic pain. Boston Scientific, an early investor in Nalu since 2017, will pay approximately $533 million in cash for the remaining equity. Nalu’s FDA-cleared Neurostimulation System uses peripheral nerve stimulation (PNS) to relieve sever

Berkeley, CA, October 17, 2025 (Valitor Press Release) -- Valitor, a biotech company developing next-generation ophthalmic medicines, named Gregory D. Kunst as its new chief executive officer and board member. Kunst brings extensive experience across ophthalmic drugs, medical devices, cell and gene therapies, and biotech commercialization, succeeding interim CEO Michael Ostrach. Kunst will lead Valitor’s advancement of VLTR-559, a long-acting anti-VEGF therapy for wet AMD,

North Carolina & Boston, October 14, 2025 (Business Wire) -- BioCryst Pharmaceuticals will acquire Astria Therapeutics for an implied equity value of $920 million and enterprise value of $700 million. The deal adds Astria’s late-stage injectable HAE therapy, navenibart, to BioCryst’s portfolio, supporting a projected double-digit growth trajectory. BioCryst expects to remain profitable and cash flow positive post-transaction, with the deal expected to close in Q1 2026. Read

Redmond, WA, October 22, 2025 (EchoNous Press Release) -- EchoNous has named Tony Titus as its new Chief Executive Officer. Titus brings over 25 years of senior leadership experience in advanced medical technology, including roles at Medtronic, Cardiac Science, Masimo, and most recently as Chief Commercial Officer at Clarius Mobile Health. Titus has spent the past 15 years building global sales and marketing teams, distribution networks, and business development partnership

Marlborough, MA & New York, October 21, 2025 (Business Wire) -- Hologic, a global leader in women’s health, announced a definitive agreement to be acquired by investment firms Blackstone and TPG for up to $79 per share, valuing the transaction at $18.3 billion. The deal offers shareholders $76 in cash plus a contingent value right of up to $3 per share, tied to revenue milestones in Hologic’s Breast Health business for fiscal 2026 and 2027. Supported by minority investments

San Clemente, CA, October 6, 2025 (PRNewswire) -- AtaCor Medical secured $75 million to support its U.S. FDA pivotal study of the...

Boston, MA, October 3, 2025 (PRNewswire) -- Solarea Bio announced the appointment of Catherine Balsam-Schwaber as Chief Executive...

San Diego, CA, September 30, 2025 (Reuters) -- Crystalys Therapeutics announced its launch from stealth with a $205 million Series A...

Nashville, TN, October 6, 2025 (Globe Newswire) -- Harrow (Nasdaq: HROW) announced leadership changes at its subsidiary ImprimisRx,...